Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The influenza virus hemagglutinin (HA) stem (or stalk) is a highly conserved region of the viral surface glycoprotein hemagglutinin, which plays a critical role in viral entry and infection. Unlike the highly variable globular head of HA, which is subject to rapid antigenic drift, the stem region remains relatively unchanged across diverse influenza strains and subtypes. This high conservation makes the HA stem a premier target for the development of broadly neutralizing antibodies (bnAbs), small-molecule fusion inhibitors, and universal influenza vaccines.
Therapeutic agents targeting the HA stem, such as the monoclonal antibodies MEDI8852, VIS410, and VIR-2482, or small molecules like JNJ-4796, function primarily by binding to the stem and locking it in its prefusion conformation. This blocks the low pH-induced conformational changes required for the fusion of the viral envelope with the host endosomal membrane, thereby preventing viral genome release into the host cell. Additionally, stem-binding antibodies can recruit host immune cells to eliminate infected cells via Fc-mediated effector functions like antibody-dependent cellular cytotoxicity (ADCC). Despite their preclinical promise, several stem-targeting candidates have faced challenges in clinical trials, including limited mucosal penetration and a lack of robust clinical efficacy, highlighting the ongoing need for optimized delivery and design.
Inhibition of viral membrane fusion by preventing low pH-induced conformational changes of hemagglutinin, and recruitment of Fc-mediated effector functions such as antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP).
8 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Influenza virus hemagglutinin stem (HA stem).